2026年1月20日 被推翻的CEO Tim Kutzkey 在公司股票上购买了353K美元 尽管季度损失和负利润 Surrozen CEO Tim Kutzkey bought $353K in company stock on Jan. 20, 2026, despite quarterly losses and negative profitability.

2026年1月20日, Surrozen Director Tim Kutzkey购买18 052股,每股19.60美元,股份增加到1,016 658股,价值约1993万美元。 On January 20, 2026, Surrozen director Tim Kutzkey bought 18,052 shares at $19.60 each, increasing his stake to 1,016,658 shares, valued at about $19.93 million. 在此之前,最近进行了一系列采购,包括11月13日大宗购置315 457份股票,价值12.65美元。 This follows a series of recent purchases, including a large November 13 acquisition of 315,457 shares at $12.65. 该公司是一家临床生物制药公司,开发Wnt定点治疗道,报告每季度每股损失3.61美元,缺少估计,利润指数为负值。 The company, a clinical-stage biopharmaceutical firm developing Wnt pathway-targeting therapies, reported a quarterly loss of $3.61 per share, missing estimates, and has negative profitability metrics. 股价在1月20日为17.98美元, 市场上限为1.5409亿美元, 且共识为“Moderate Buy”, 目标价格为32.00美元。 The stock traded at $17.98 on January 20, with a market cap of $154.09 million and a consensus "Moderate Buy" rating, a target price of $32.00.